



ASX ANNOUNCEMENT

18 March 2015

Cynata Presenting at BIT's 8th Annual World Congress of Regenerative Medicine & Stem Cell – Korea (RMSC-2015 Korea), March 19th to March 21st

CEO Ross Macdonald to Chair “Mesenchymal Stem Cell Session”

Melbourne, Australia March 18, 2015: Stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX: CYP) announced today CEO and Managing Director, Dr Ross Macdonald, will be participating and chairing a session at BIT's 8th Annual World Congress of Regenerative Medicine & Stem Cell – Korea (RMSC-2015 Korea). Dr Macdonald will chair Session 407: “Mesenchymal Stem Cell” on March 20. He will also present on Cynata's Cymerus™ technology.

The conference will bring together leading industry representatives, researchers, policymakers, regulators, and investors, who will share advances and future trends in regenerative medicine and stem cells.

Dr Macdonald stated, “I am very pleased to have the opportunity to represent Cynata at such a prestigious conference. This conference provides the chance for participants to share research, business planning, strategic partnering discussions, and hold conversations with potential investors.”

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA technology provides a consistent, reliable source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

CONTACTS: Dr. Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Dr. Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com
Kirin Smith, Chief Operations Officer, Investor Contact, + 1 646-863-6519, ksmith@pcgadvisory.com
Sean Leous, Chief Communications Officer, Media Contact, +1 646-863-8998, sleous@pcgadvisory.com